Skip to main content

Table 2 When the total antibody is positive, the change in the number of IgA, IgM, IgG, Nabs positive patients with and without underlying disease

From: Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan

Total antibody positive population (No.)

Underlying disease or not (No.)

IgA + (%)

IgM + (%)

IgG + (%)

Nabs + (%)

Baseline (313)

No (216)

43 (19.91%)

26 (12.04%)

216 (100.00%)

92 (42.59%)

Yes (97)

22 (22.68%)

7 (7.22%)

97 (100.00%)

43 (44.33%)

First follow-up (212)

No (146)

16 (10.96%)

4 (2.74%)

145 (99.32%)

67 (45.89%)

Yes (66)

11 (16.67%)

1 (1.52%)

66 (100.00%)

35 (53.03%)

Second follow-up (238)

No (170)

11 (6.47%)

3 (1.76%)

168 (98.82%)

88 (51.76%)

Yes (68)

6 (8.82%)

1 (1.47%)

63 (92.65%)

36 (52.94%)

  1. Nabs neutralising antibody titres